1. Pink Sheet
  2. >>Product Reviews
  3. >>Post-Marketing Regulation & Studies

Sentinel’s “IMPACT” Beyond Safety: Anti-Coagulant Study Is Early Test

 
• By Cole Werble

The Sentinel post-marketing surveillance system is up and running. Now, FDA is ready to explore uses beyond safety.

FDA is close to taking the first concrete step toward opening up use of its Sentinel post-market surveillance network to investigate questions beyond safety: the agency may be ready as early as next year to unveil a project (the IMPACT-AF Trial) that could lead to outreach to patients who are under-utilizing anti-coagulant drugs.

The IMPACT project will attempt to use Sentinel to identify patients with atrial fibrillation who may be candidates for therapy with anticoagulants

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Post-Marketing Regulation & Studies

More from Product Reviews

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.